News | Radiopharmaceuticals and Tracers | September 11, 2015

Zevacor Installs First Medical-only 70 MeV Cyclotron in U.S.

Cyclone 70P to stabilize U.S. supply of Strontium 82, produce next generation of radiopharmaceutical products

Zevacor, IBA, 70 MeV cyclotron, Cyclone 70P, radiopharmaceuticals

September 11, 2015 — Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, announced the arrival of a 70 MeV Cyclotron at its new production facility in Noblesville, Indiana.

The 140-ton Cyclone 70P, manufactured in Belgium by Ion Beam Applications S.A (IBA), is the first commercial 70 MeV cyclotron dedicated to medical use in the United States. Expected to be fully operational in the first quarter of 2016, the cyclotron is being installed in a new, state-of-the-art high capacity manufacturing center. The center will house a complement of radioisotope synthesis equipment able to produce a broad range of radiopharmaceuticals for clinical and research applications.

The initial primary focus of the 70 MeV cyclotron will be the commercial manufacture of Strontium 82 to ensure an ample, stable U.S.-based supply of Strontium 82/Rubidium 82 generators for use in the diagnosis of cardiovascular disease. The cyclotron will also be employed to produce a wide variety of other radionuclides for both research and clinical applications.

The Cyclone 70P is an optimized, high-power proton cyclotron with variable proton acceleration in the energy range of 30 to 70 MeV. The 140-ton unit has two ports, six beam lines and capabilities for solid, liquid and gas targets.

For more information: www.iba-worldwide.com


Related Content

News | Radiopharmaceuticals and Tracers

March 27, 2025 — GE HealthCare is announcing the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the 2025 ...

Home March 25, 2025
Home
News | Radiopharmaceuticals and Tracers

April 13, 2023 — A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin ...

Home April 13, 2023
Home
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Home November 05, 2022
Home
News | Radiopharmaceuticals and Tracers

June 24, 2022 — Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive ...

Home June 24, 2022
Home
News | Radiopharmaceuticals and Tracers

August 2, 2019 — The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) ...

Home August 02, 2019
Home
News | Radiopharmaceuticals and Tracers

July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot ...

Home July 16, 2019
Home
News | Radiopharmaceuticals and Tracers

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel ...

Home June 05, 2019
Home
News | Radiopharmaceuticals and Tracers

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular ...

Home May 17, 2019
Home
News | Radiopharmaceuticals and Tracers | Jeff Zagoudis, Associate Editor

May 10, 2019 — Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in ...

Home May 10, 2019
Home
News | Radiopharmaceuticals and Tracers

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide ...

Home October 12, 2018
Home
Subscribe Now